Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01734473 · ClinicalTrials.gov registry record · NA

Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD)

A NA study, sponsored by Texas A&M University.

Completed
Registry status
NA
Development phase
36
Enrollment target

NCT01734473: Completed NA study, sponsored by Texas A&M University.

NCT01734473 is a NA study that has completed, run by Texas A&M University. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01734473, a NA study, has completed, sponsored by Texas A&M University.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target

Study Summary

Weight loss commonly occurs in patients with COPD, negatively influencing their quality of life, treatment response and survival. Loss of muscle protein is generally a central component of this weight loss and independently increases mortality. This study will provide relevant clinical information in regards to the anabolic properties of specific dietary substrates and their co-active anabolic effects. Hypotheses: 1) That supplementation of a hydrolyzed casein-based protein meal with the addition of carbohydrates is more anabolic than a hydrolyzed casein-based protein meal without carbohydrates in COPD patients and healthy older adults; 2) That leucine addition to a hydrolyzed casein-based protein meal only enhances the protein anabolic response in COPD patients and healthy older adults when carbohydrates are not added to the protein meal; 3) That COPD patients have a more efficient protein anabolic response to a hydrolyzed casein-based protein meal than healthy older adults. A fifth study day was added to measure protein requirements of included individuals to be able to interpret their response to the other interventions on the other study days, and to test the hypothesis that subjects with lower protein requirements respond less to intervention with leucine and/or carbohydrates. For the 5th additional test day we will first approach the 10 COPD and 10 healthy subjects who already completed the first 4 study days (and signed the re-contact form) to come back for this extra test day. We will (pre-)screen these subjects by phone for eligibility and check for changes in their recent medical history (with help of the (pre-)screening questionnaires in CRF). If all inclusion criteria are still met, these subjects will be asked to provide a written re-consent. If necessary, we will recruit new subjects who will complete only one of the four test days (i.e. the test day on which the hydrolyzed casein-based protein meal with carbohydrates is provided) and the additional 5

Primary Outcome

Change in net whole-body protein synthesis (whole-body protein synthesis - whole-body protein breakdown)

Interventions

  • DIETARY_SUPPLEMENT Hydrolyzed casein protein
  • DIETARY_SUPPLEMENT Hydrolyzed casein protein + carbohydrates
  • DIETARY_SUPPLEMENT Hydrolyzed casein protein + leucine
  • DIETARY_SUPPLEMENT Hydrolyzed casein protein + carbohydrates + leucine
  • DIETARY_SUPPLEMENT 4 levels of hydrolyzed casein protein + carbohydrates

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2012-11-28
Est. Completion 2015-05-27
Phase NA
Texas A&M University

95 total trials

What the finished NCT01734473 record still lists

NCT01734473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 5 interventions - of which Hydrolyzed casein protein is the first listed.

NCT01734473 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01734473 about?

NCT01734473 is a clinical study titled "Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD)". Weight loss commonly occurs in patients with COPD, negatively influencing their quality of life, treatment response and survival. Loss of muscle protein is generally a central component of this weight loss and independently increases mortality. This study will provide relevant clinical information i...

What is the current status of trial NCT01734473?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2012-11-28. Estimated completion is 2015-05-27.

What interventions are being tested in trial NCT01734473?

The interventions under investigation include: Hydrolyzed casein protein (DIETARY_SUPPLEMENT), Hydrolyzed casein protein + carbohydrates (DIETARY_SUPPLEMENT), Hydrolyzed casein protein + leucine (DIETARY_SUPPLEMENT), Hydrolyzed casein protein + carbohydrates + leucine (DIETARY_SUPPLEMENT), 4 levels of hydrolyzed casein protein + carbohydrates (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01734473?

This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01734473's enrollment target sits among peer trials

36 1541st of 2000 higher than 437 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01734473, the US trial registry maintained by the National Library of Medicine. NCT01734473 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.